Cargando…
Medical Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third leading cause of cancer-related deaths worldwide. Cirrhosis, most often due to viral hepatitis, is the predominant risk factors for HCC and geographical differences in both risk factors and incidence are largely due to ep...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033123/ https://www.ncbi.nlm.nih.gov/pubmed/21415957 http://dx.doi.org/10.4084/MJHID.2009.021 |
_version_ | 1782197542707003392 |
---|---|
author | Granito, Alessandro Bolondi, Luigi |
author_facet | Granito, Alessandro Bolondi, Luigi |
author_sort | Granito, Alessandro |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third leading cause of cancer-related deaths worldwide. Cirrhosis, most often due to viral hepatitis, is the predominant risk factors for HCC and geographical differences in both risk factors and incidence are largely due to epidemiological variations in hepatitis B and C infection. Hepatic function is a relevant parameter in selecting therapy in HCC. The current clinical classification of HCC split patients into 5 stages, with a specific treatment schedule for any stage. As patients with early stages can receive curative treatments, such as surgical resection, liver transplantation or local ablation, surveillance program in high-risk populations has become mandatory. Sorafenib, a multikinase inhibitor, has recently shown survival benefits in patients at advanced stage of disease. Hopefully, new molecular targeted therapies and their combination with sorafenib or interventional and surgical procedures, should expand the therapeutic armamentarium against HCC. |
format | Text |
id | pubmed-3033123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-30331232011-03-17 Medical Treatment of Hepatocellular Carcinoma Granito, Alessandro Bolondi, Luigi Mediterr J Hematol Infect Dis Review Article Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third leading cause of cancer-related deaths worldwide. Cirrhosis, most often due to viral hepatitis, is the predominant risk factors for HCC and geographical differences in both risk factors and incidence are largely due to epidemiological variations in hepatitis B and C infection. Hepatic function is a relevant parameter in selecting therapy in HCC. The current clinical classification of HCC split patients into 5 stages, with a specific treatment schedule for any stage. As patients with early stages can receive curative treatments, such as surgical resection, liver transplantation or local ablation, surveillance program in high-risk populations has become mandatory. Sorafenib, a multikinase inhibitor, has recently shown survival benefits in patients at advanced stage of disease. Hopefully, new molecular targeted therapies and their combination with sorafenib or interventional and surgical procedures, should expand the therapeutic armamentarium against HCC. Università Cattolica del Sacro Cuore 2009-12-16 /pmc/articles/PMC3033123/ /pubmed/21415957 http://dx.doi.org/10.4084/MJHID.2009.021 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Granito, Alessandro Bolondi, Luigi Medical Treatment of Hepatocellular Carcinoma |
title | Medical Treatment of Hepatocellular Carcinoma |
title_full | Medical Treatment of Hepatocellular Carcinoma |
title_fullStr | Medical Treatment of Hepatocellular Carcinoma |
title_full_unstemmed | Medical Treatment of Hepatocellular Carcinoma |
title_short | Medical Treatment of Hepatocellular Carcinoma |
title_sort | medical treatment of hepatocellular carcinoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033123/ https://www.ncbi.nlm.nih.gov/pubmed/21415957 http://dx.doi.org/10.4084/MJHID.2009.021 |
work_keys_str_mv | AT granitoalessandro medicaltreatmentofhepatocellularcarcinoma AT bolondiluigi medicaltreatmentofhepatocellularcarcinoma |